- Home
- LUNG
LUNG
Pulmonx Corporation
as 07-26-2024 4:00pm EST
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Upcoming Earnings Alert:
Get ready for potential market movements as Pulmonx Corporation LUNG prepares to release earnings report on 31 Jul 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 349.3M | IPO Year: | 2020 |
| Target Price: | $15.25 | AVG Volume (30 days): | 273.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.67 - $14.84 | Next Earning Date: | 07-31-2024 |
| Revenue: | $72,994,000 | Revenue Growth: | 27.14% |
| Revenue Growth (this year): | 22.68% | Revenue Growth (next year): | 18.85% |
Stock Insider Trading Activity of Pulmonx Corporation (LUNG)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Jun 24 '24 | Sell | $6.16 | 1,184 | $7,293.44 | 300,019 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Jun 3 '24 | Sell | $6.97 | 1,510 | $10,524.70 | 301,203 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Jun 3 '24 | Sell | $6.97 | 1,724 | $12,016.28 | 302,713 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Jun 3 '24 | Sell | $6.97 | 678 | $4,725.66 | 304,437 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Jun 3 '24 | Sell | $6.97 | 385 | $2,683.45 | 305,115 | SEC Form 4 |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Jun 3 '24 | Sell | $6.97 | 1,603 | $11,172.91 | 209,113 | SEC Form 4 |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Jun 3 '24 | Sell | $6.97 | 2,744 | $19,125.68 | 210,716 | SEC Form 4 |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Jun 3 '24 | Sell | $6.97 | 719 | $5,011.43 | 213,460 | SEC Form 4 |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Jun 3 '24 | Sell | $6.97 | 409 | $2,850.73 | 214,179 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | May 22 '24 | Sell | $8.71 | 1,184 | $10,312.64 | 305,500 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Apr 22 '24 | Sell | $7.49 | 1,184 | $8,868.16 | 306,684 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Mar 22 '24 | Sell | $9.36 | 1,184 | $11,082.24 | 307,868 | SEC Form 4 |
| McKune John | LUNG | INTERIM CFO | Mar 1 '24 | Sell | $9.06 | 155 | $1,404.30 | 48,333 | SEC Form 4 |
| McKune John | LUNG | INTERIM CFO | Mar 1 '24 | Sell | $9.06 | 254 | $2,301.24 | 48,079 | SEC Form 4 |
| McKune John | LUNG | INTERIM CFO | Mar 1 '24 | Sell | $9.06 | 669 | $6,061.14 | 47,410 | SEC Form 4 |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Mar 1 '24 | Sell | $9.06 | 459 | $4,158.54 | 149,380 | SEC Form 4 |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Mar 1 '24 | Sell | $9.06 | 809 | $7,329.54 | 148,571 | SEC Form 4 |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Mar 1 '24 | Sell | $9.06 | 3,083 | $27,931.98 | 145,488 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Mar 1 '24 | Sell | $9.06 | 428 | $3,877.68 | 242,621 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Mar 1 '24 | Sell | $9.06 | 753 | $6,822.18 | 241,868 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Mar 1 '24 | Sell | $9.06 | 1,916 | $17,358.96 | 239,952 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Feb 22 '24 | Sell | $14.20 | 1,184 | $16,812.80 | 243,049 | SEC Form 4 |
| French Glendon E. III | LUNG | PRESIDENT AND CEO | Feb 15 '24 | Sell | $14.60 | 20,000 | $292,000.00 | 1,121,344 | SEC Form 4 |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Jan 22 '24 | Sell | $13.13 | 1,184 | $15,545.92 | 244,233 | SEC Form 4 |
| French Glendon E. III | LUNG | PRESIDENT AND CEO | Jan 18 '24 | Sell | $12.77 | 10,000 | $127,700.00 | 1,141,344 | SEC Form 4 |
Latest Pulmonx Corporation News
LUNG Breaking Stock News: Dive into LUNG Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
Simply Wall St.
2 months ago
OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
Barrons.com
2 months ago
Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
Simply Wall St.
2 months ago
Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
Compare LUNG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LUNG Pulmonx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.